Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.70 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | F7 | P08709 | 2/20 | 0.52 |
| ▸ | F3 | P13726 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 4/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10445375 | 1.00 | EPHX2 (0.70) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL10445592 | 1.00 | EPHX2 (0.70) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL10445591 | 1.00 | EPHX2 (0.70) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL2219389 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL4092435 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL9777847 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL11370740 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL1962429 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL8349583 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH | |
| SCHEMBL11370737 | 0.96 | EPHX2 (0.75) | EPHX2PPARAF7F3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023196931-A1 | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023137550-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023050003-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-0355842-A2 | External preparation | Sansho Seiyaku Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2176/4885PPARA 1870/4885F7 1893/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2176/4885PPARA 1870/4885F7 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.